| Identification | Back Directory | [Name]
PF-06726304 acetate | [CAS]
2080306-28-9 | [Synonyms]
PF 06726304 acetate,PF06726304 acetate | [Molecular Formula]
C24H25Cl2N3O5 | [MDL Number]
MFCD30480912 | [MOL File]
2080306-28-9.mol | [Molecular Weight]
506.38 |
| Hazard Information | Back Directory | [in vivo]
PF-06726304 (200 and 300 mg/kg; BID for 20 days) inhibits tumor growth and induces robust modulation of downstream biomarkers in a subcutaneous Karpas-422 xenograft model[1]. | Animal Model: | Female Scid beige mice (6-8 weeks old) with Karpas-422 xenograft model[1] | | Dosage: | 200 and 300 mg/kg | | Administration: | Given BID for 20 days | | Result: | Inhibited tumor growth and induced robust modulation of downstream biomarkers in a subcutaneous Karpas-422 xenograft model. |
| [IC 50]
EZH2 WT: 0.7 nM (Ki); EZH2 Y641N: 3.0 nM (Ki) | [storage]
Store at RT | [References]
[1] Kung PP, et al. Design and Synthesis of Pyridone-Containing 3,4-Dihydroisoquinoline-1(2H)-ones as a Novel Class of Enhancer of Zeste Homolog 2 (EZH2) Inhibitors. J Med Chem. 2016 Sep 22;59(18):8306-25. DOI:10.1021/acs.jmedchem.6b00515 |
|
|